Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension

Gomis, R; Owens, D. R; Taskinen, M.-R; Prato, S. Del; Patel, S; Pivovarova, A; Schlosser, A; Woerle, H.-J; Owens, David

doi:10.1111/j.1742-1241.2012.02975.x

Journal article 762 views

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week...

R Gomis, D. R Owens, M.-R Taskinen, S. Del Prato, S Patel, A Pivovarova, A Schlosser, H.-J Woerle, David Owens

International Journal of Clinical Practice, Volume: 66, Issue: 8, Pages: 731 - 740

Swansea University Author: David Owens

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1111/j.1742-1241.2012.02975.x

Published in:	International Journal of Clinical Practice
ISSN:	1368-5031
Published:	2012
Online Access:	Check full text
URI:	https://cronfa.swan.ac.uk/Record/cronfa13270
Tags:	Add Tag No Tags, Be the first to tag this record!

first_indexed	2013-07-23T12:09:52Z
last_indexed	2018-02-09T04:43:55Z
id	cronfa13270
recordtype	SURis
fullrecord	<?xml version="1.0"?><rfc1807><datestamp>2011-10-01T00:00:00.0000000</datestamp><bib-version>v2</bib-version><id>13270</id><entry>2012-11-15</entry><title>Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension</title><swanseaauthors><author><sid>2fd4b7c3f82c6d3bd546eff61ff944e9</sid><ORCID>0000-0003-1002-1238</ORCID><firstname>David</firstname><surname>Owens</surname><name>David Owens</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2012-11-15</date><deptcode>BMS</deptcode><abstract></abstract><type>Journal Article</type><journal>International Journal of Clinical Practice</journal><volume>66</volume><journalNumber>8</journalNumber><paginationStart>731</paginationStart><paginationEnd>740</paginationEnd><publisher/><placeOfPublication/><issnPrint>1368-5031</issnPrint><issnElectronic/><keywords/><publishedDay>31</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2012</publishedYear><publishedDate>2012-12-31</publishedDate><doi>10.1111/j.1742-1241.2012.02975.x</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2011-10-01T00:00:00.0000000</lastEdited><Created>2012-11-15T17:22:46.6872746</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>R</firstname><surname>Gomis</surname><order>1</order></author><author><firstname>D. R</firstname><surname>Owens</surname><order>2</order></author><author><firstname>M.-R</firstname><surname>Taskinen</surname><order>3</order></author><author><firstname>S. Del</firstname><surname>Prato</surname><order>4</order></author><author><firstname>S</firstname><surname>Patel</surname><order>5</order></author><author><firstname>A</firstname><surname>Pivovarova</surname><order>6</order></author><author><firstname>A</firstname><surname>Schlosser</surname><order>7</order></author><author><firstname>H.-J</firstname><surname>Woerle</surname><order>8</order></author><author><firstname>David</firstname><surname>Owens</surname><orcid>0000-0003-1002-1238</orcid><order>9</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling	2011-10-01T00:00:00.0000000 v2 13270 2012-11-15 Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension 2fd4b7c3f82c6d3bd546eff61ff944e9 0000-0003-1002-1238 David Owens David Owens true false 2012-11-15 BMS Journal Article International Journal of Clinical Practice 66 8 731 740 1368-5031 31 12 2012 2012-12-31 10.1111/j.1742-1241.2012.02975.x COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2011-10-01T00:00:00.0000000 2012-11-15T17:22:46.6872746 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine R Gomis 1 D. R Owens 2 M.-R Taskinen 3 S. Del Prato 4 S Patel 5 A Pivovarova 6 A Schlosser 7 H.-J Woerle 8 David Owens 0000-0003-1002-1238 9
title	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
spellingShingle	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension David Owens
title_short	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
title_full	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
title_fullStr	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
title_full_unstemmed	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
title_sort	Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension
author_id_str_mv	2fd4b7c3f82c6d3bd546eff61ff944e9
author_id_fullname_str_mv	2fd4b7c3f82c6d3bd546eff61ff944e9_***_David Owens
author	David Owens
author2	R Gomis D. R Owens M.-R Taskinen S. Del Prato S Patel A Pivovarova A Schlosser H.-J Woerle David Owens
format	Journal article
container_title	International Journal of Clinical Practice
container_volume	66
container_issue	8
container_start_page	731
publishDate	2012
institution	Swansea University
issn	1368-5031
doi_str_mv	10.1111/j.1742-1241.2012.02975.x
college_str	Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id	facultyofmedicinehealthandlifesciences
hierarchy_top_title	Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id	facultyofmedicinehealthandlifesciences
hierarchy_parent_title	Faculty of Medicine, Health and Life Sciences
department_str	Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str	0
active_str	0
published_date	2012-12-31T03:15:13Z
_version_	1763750249079242752
score	11.0128355

Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week...

Similar Items